TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03228407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Confocal endomicroscopy
Description: Confocal laser endomicroscopy (CLE) permits real-time in-vivo histologic analysis of esophageal mucosa at the time of upper endoscopy. The technology is based on the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. Because CLE relies upon tissue fluorescence, intravenous fluorescein is generally used to highlight the vasculature and intercellular spaces of the tissue being examined.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biopsies
Description: Additional biopsies will be obtained of the esophageal mucosa.These will be obtained with a standard biopsy forceps inserted through the channel in gastroscope.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopic biopsies
Description: Additional biopsies will be obtained of the esophageal mucosa.These will be obtained with a standard biopsy forceps inserted through the channel in gastroscope.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biopsies
Description: Additional biopsies will be obtained of the esophageal mucosa.These will be obtained with a standard biopsy forceps inserted through the channel in gastroscope.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mucosal impedance (MI)
Description: MI balloon measures epithelial impedance along a 10 cm length of esophagus. The gastroscope will be withdrawn and the MI balloon will be advanced into the esophagus through the mouth. The balloon will be inflated so that the sensors contact the esophageal mucosa. After MI measurements are obtained, the balloon will be deflated and withdrawn.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Mucosal impedance (MI)
Description: MI balloon measures epithelial impedance along a 10 cm length of esophagus. The gastroscope will be withdrawn and the MI balloon will be advanced into the esophagus through the mouth. The balloon will be inflated so that the sensors contact the esophageal mucosa. After MI measurements are obtained, the balloon will be deflated and withdrawn.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mucosal impedance (MI)
Description: MI balloon measures epithelial impedance along a 10 cm length of esophagus. The gastroscope will be withdrawn and the MI balloon will be advanced into the esophagus through the mouth. The balloon will be inflated so that the sensors contact the esophageal mucosa. After MI measurements are obtained, the balloon will be deflated and withdrawn.
Study: NCT00557102

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: cetuximab

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim

Intervention type: DRUG
Group type: OTHER
Intervention: fluorouracil

Intervention type: DRUG
Group type: OTHER
Intervention: irinotecan hydrochloride
Study: NCT00840879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg Tablets
Description: 1 x 15 mg, single-dose fed
Study: NCT00557102

Intervention type: DRUG
Group type: OTHER
Intervention: leucovorin calcium
Study: NCT03878459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Description: patients will be started on 15 mg and the dose escalated to the maximal tolerated dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PATIENTS WILL RECEIVE PLACEBO
Study: NCT02505971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadolol
Description: Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day. In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be escalated (by 0.5 mg/kg/day at any following study visit) up to 3 mg/kg/day based on the clinical response to maintain the dose that led to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52.
Study: NCT00840879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mobic® 15 mg Tablets
Description: 1 x 15 mg, single-dose fed
Study: NCT06736626

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents (DES), which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of DES, and received a subsequent course of dual antiplatelet therapy (DAPT), as clinically indicated.

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents (DES), which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of DES, and received a subsequent course of dual antiplatelet therapy (DAPT), as clinically indicated.
Study: NCT02505971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day.~In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be increased by investigator, based on clinical response by 0.5 mg/kg/day at any study visit (up to 3 mg/kg/day divided twice a day) to maintain the dose that lead to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52.
Study: NCT02907944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Facilitation
Description: Implementation Facilitation is an evidence-based strategy tailored to the specific needs of the clinic, designed to increase uptake of evidence based treatments for tobacco, alcohol and opioid use disorders. Will include provider education and academic detailing.~* External Facilitator: Outside content expert who assists site~* Local Champion: Site stakeholder who promotes change~* Provider Education and Academic Detailing: Provision of unbiased peer education~* Stakeholder Engagement: Aligning goals of implementation and those impacted~* Tailor Program to Site: Addressing site specific needs based on Aim 1~* Performance Monitoring and Feedback: Assess implementation of screening and treatment efforts and inform site of results~* Formative Evaluation: Quant. and qual. determination of impact~* Establish a Learning Collaborative: Shared learning opportunities tailored to stakeholders~* Program Marketing: Increase attention to availability of on-site addiction treatment services
Study: NCT00872729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cystagon®
Description: Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.~Duration of Treatment and Dose: Reference Period up to four doses Q6H.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP103
Description: Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.~Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product.
Study: NCT03474965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Description: Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
Study: NCT03427463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: receiving 0.1 mg IT morphine
Description: Patients will receive the standard of care dose 0.1 mg of intrathecal morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recieving 0.05 mg IT morphine
Description: Patients will receive 0.05 mg of intrathecal morphine
Study: NCT03296618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSI-566
Description: Dosing will consist of a one-time stereotactic, intracranial injection of a hNSC line, NSI-566, ranging from 1.2×107 cells to 8×107 cells, as tolerated.
Study: NCT04537949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b3
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost (P/B) regimen).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b3
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost (P/B) regimen).
Study: NCT04049565

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin biomarker and CRP biomarker
Description: collecting blood samples to measure serum CRP and Procalcitonin
Study: NCT04056728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eupenta Inj.
Description: fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA \[recombinant-deoxyribonucleic acid\])-Haemophilus influenzae type b conjugate vaccine single dose 0.5 mL/vial The vaccine is given at 6, 10 and 14 weeks of age in infants.
Study: NCT01253382

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ecallantide
Description: 10 - 30mg subcutaneous injection.
Study: NCT00368368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 100mg po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 100mg po
Study: NCT01408498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
Study: NCT01253382

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ecallantide
Description: 10 - 30mg subcutaneous injection.
Study: NCT00368368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 100mg po
Study: NCT03876353

Intervention type: OTHER
Group type: OTHER
Intervention: Floss
Description: All participants will have half of their mouth flossed. Each participant will act as their own control.

Intervention type: OTHER
Group type: OTHER
Intervention: Floss
Description: All participants will have half of their mouth flossed. Each participant will act as their own control.
Study: NCT03828994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tech-PN
Description: * text messaging(daily medication reminders and tri-weekly messages following the 14-day treatment period)~* enhanced community health nurse visits on day 3-5, 14 and 30~* field based treatment visits~* clinical assistance with notification, testing and treatment
Study: NCT02281084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg by IV infusion on Day 1 of each 28 day treatment cycle.
Study: NCT02186067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral System
Description: Primary Level:~Refer patients to secondary care centre if Patients has complicated hypertension (Patients with target organ damage, CVD, CKD or more the 3 drugs)~Secondary Level:~Community health center at Aga Khan University will serve as the secondary care center.~Family physician will manage patients with CVD, CKD or more than 3 drugs.~Tertiary care:~Cardiologist at the Aga Khan University will manage secondary, resistant and difficult to treat hypertension.~Behavioral: Other Interventions CME session by Cardiologist/Consultant Family Physician : At start , and at two months Community screening by Family physicians at the primary care center (open house) once in three months Patient group education session. Once in three months
Study: NCT03192020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous needle fasciotomy (PNF)
Description: The division of the cord can be made under local anesthesia in the clinic and takes only a few minutes to perform. It can be performed whenever the cord is palpable. There are only puncture wounds left, and hence, the patient can start normal use of the hand the day after the procedure. If patient seeks for a treatment and the recurrence of the disease can not be treated by the PNF or patient is not willing to new PNF patient will be treated with LF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex]
Description: CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord at least three different places in the outpatient clinic and the cord can be ruptured by gently force after one to three days. If patient seeks for a treatment and the recurrence of the disease can not be treated by the CCH or patient is not willing to new CCH patient will be treated with LF.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited fasciectomy (LF)
Description: LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limited fasciectomy (LF)
Description: LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited fasciectomy (LF)
Description: LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.
Study: NCT03382600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Q3W on Day 1 by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Q3W on Day 1 by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 Q3W on Day 1 by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: 40 to 60 mg orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
Study: NCT03158584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Intrathecal administration of Morphine in children undergoing major abdominal surgeries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Intrathecal administration of Morphine in children undergoing major abdominal surgeries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Intrathecal administration of Morphine in children undergoing major abdominal surgeries
Study: NCT01217749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 420 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 420 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 420 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: per package insert as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: per package insert as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: per package insert as an IV infusion
Study: NCT04439578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin
Description: 600 mg rifampicin was administered in the morning.
Study: NCT04442646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary lessons
Description: the multidisciplinary lessons will be conducted by study staff, formed by pneumologist, nurse, biologist and respiratory therapist once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day
Study: NCT04529772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Investigational Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Investigational Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Investigational Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Investigational Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Investigational Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Investigational Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Investigational Product
Study: NCT04825314

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urethral catheter
Description: All Patients will have urethral catheterization with either Noble Metal Alloy coated catheter or Silicon Foley catheter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urethral catheter
Description: All Patients will have urethral catheterization with either Noble Metal Alloy coated catheter or Silicon Foley catheter.
Study: NCT01083719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: Fluoro-deoxy gluocose-Positron emission tomography for delineating volumes in Glioblastoma
Study: NCT00477594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium
Description: 200 mg/ml, in 1 ml solution for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium
Description: 200 mg/ml, in 1 ml solution for subcutaneous injection.
Study: NCT00418561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhASA - Dose Level 1
Description: Intravenous infusion 25 U/kg as a single dose - hereafter 50 U/kg every other week for 26 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhASA - Dose Level 2
Description: Intravenous infusion 100 U/kg every other week for 26 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhASA - Dose Level 3
Description: Intravenous infusion 200 U/kg every other week for 26 weeks
Study: NCT03083574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photopheresis Theraflex ECP™
Description: The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.
Study: NCT03081481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX302
Description: Single prostate cancer lesion injected with PRX302
Study: NCT03919435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim Sulfamethoxazole
Description: Dosage: 160mg-800mg Frequency: 2 times a day Dosage Form: Pill (oral) Duration: 4 weeks
Study: NCT05620511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction
Description: Mindfulness based stress reduction v.s.Relaxation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness based stress reduction
Description: Mindfulness based stress reduction v.s.Relaxation
Study: NCT02566122

Intervention type: OTHER
Intervention: measurements
Study: NCT00840866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefprozil
Description: 500 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefzil®
Description: 500 mg Tablet
Study: NCT01501955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metaphyseal Hip Prosthesis
Description: Metaphyseal Hip Prosthesis (MHP) hip replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stanmore
Description: Stanmore hip prosthesis
Study: NCT00781339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate
Description: 0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
Study: NCT01010503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: tocilizumab 8 mg/kg intravenous infusion once in 4 weeks